Search

Incyte Corp

Suletud

SektorTervishoid

120.59 1.94

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

119.54

Max

120.8

Põhinäitajad

By Trading Economics

Sissetulek

282M

586M

Müük

401M

1.7B

P/E

Sektori keskmine

15.087

68.51

Aktsiakasum

2.8

Kasumimarginaal

34.982

Töötajad

2,844

EBITDA

384M

752M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+7.78% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

27. okt 2026

Turustatistika

By TradingEconomics

Turukapital

257M

24B

Eelmine avamishind

118.65

Eelmine sulgemishind

120.59

Uudiste sentiment

By Acuity

23%

77%

51 / 340 Pingereas Healthcare

Incyte Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. aug 2026, 19:44 UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

5. aug 2026, 19:56 UTC

Incyte Corp shares are lower today, retracing from earlier session gains. No specific news was identified to explain the decline.

4. aug 2026, 19:46 UTC

News

Mizuho raised its price target on Incyte Corp to $137, maintaining an Outperform rating. Analyst Josh Brown's comments on CNBC contributed to positive sentiment today.

3. aug 2026, 23:56 UTC

Incyte Corp shares are higher in after-market hours, recovering from five consecutive daily declines. Broader market sentiment remains positive amid declining oil prices.

31. juuli 2026, 22:21 UTC

Incyte Corp's shares are higher in after-market trading, driven by a rise in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

30. juuli 2026, 23:56 UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of declines since Thursday's close amid broader market pressures.

29. juuli 2026, 22:51 UTC

Event

Incyte Corp shares are higher after the European Commission approved Opzelura® for moderate atopic dermatitis treatment. Market conditions are also advancing in after-market trading.

28. juuli 2026, 23:02 UTC

Incyte Corp shares are lower in after-market hours amid a broader market decline influenced by concerns over technology stocks and geopolitical tensions.

27. juuli 2026, 23:02 UTC

Incyte Corp shares are lower in after-market hours, following a decline earlier in the session amid broader market sentiment influenced by falling crude oil prices.

24. juuli 2026, 21:01 UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment was affected by a sharp Nasdaq decline.

22. juuli 2026, 20:04 UTC

Incyte Corp's shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average and near the upper end of its one-month range.

21. juuli 2026, 16:36 UTC

Social Media
News

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to gains in Incyte shares during Tuesday's session.

20. juuli 2026, 21:56 UTC

Incyte Corp shares are lower in after-market hours following a volatile session, despite trading above the 20-day moving average and near a one-month high.

17. juuli 2026, 23:16 UTC

Incyte Corp shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the movement.

16. juuli 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours amid a broader market decline, influenced by rising interest rates and geopolitical tensions.

15. juuli 2026, 19:16 UTC

News

Incyte Corp remains elevated above its 20-day moving average, recently surpassing Weyerhaeuser to become the 400th largest company in the S&P 500.

13. juuli 2026, 16:21 UTC

News
Event

Incyte Corp shares are lower amid concerns over revenue guidance despite positive Phase 1/2 data for latarcibart presented at ISTH 2026 Congress.

10. juuli 2026, 20:06 UTC

Incyte Corp's shares are lower today, influenced by declines in the Biotechnology sub-sector. The stock peaked early before steadily declining throughout the session.

9. juuli 2026, 23:56 UTC

Incyte Corp shares are lower in after-market hours amid broader market caution linked to renewed military tensions between the U.S. and Iran.

8. juuli 2026, 20:04 UTC

Incyte Corp shares are lower as biotechnology stocks face pressure. The broader sector's significant losses have impacted Incyte's performance today.

7. juuli 2026, 23:06 UTC

Incyte Corp shares are lower in after-market hours amid a broader market decline. No specific company news has been identified to influence the price.

6. juuli 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, approaching the upper end of their one-month trading range. No specific news was identified for this movement.

3. juuli 2026, 00:01 UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market conditions may be influencing investor sentiment.

2. juuli 2026, 23:01 UTC

Incyte Corp shares declined in after-market hours amid notable volatility, contrasting with three consecutive sessions of gains. No specific news was identified for the move.

1. juuli 2026, 21:01 UTC

Incyte Corp shares are higher in after-market trading, reflecting a notable increase as they approach the upper end of their one-month range.

30. juuni 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, maintaining an upward trend despite broader market declines, particularly in the tech sector.

29. juuni 2026, 23:16 UTC

Event

Incyte Corp shares are higher in after-market trading following positive results from the Phase 2b trial of EVO756 for chronic spontaneous urticaria.

26. juuni 2026, 23:51 UTC

Event

Incyte Corp shares are higher in after-market trading following a positive recommendation for Opzelura® cream from the European Medicines Agency's Committee for Medicinal Products.

25. juuni 2026, 23:51 UTC

Incyte Corp shares are higher in after-market hours, recovering from an earlier session low. Broader market performance remains mixed amid varying tech stock results.

24. juuni 2026, 20:02 UTC

News
Social Media

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to the stock's advance amid positive social media sentiment.

Võrdlus sarnastega

Hinnamuutus

Incyte Corp Prognoos

Hinnasiht

By TipRanks

7.78% tõus

12 kuu keskmine prognoos

Keskmine 129.94 USD  7.78%

Kõrge 155 USD

Madal 109 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Incyte Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

20 ratings

10

Osta

10

Hoia

0

Müü

Sentiment

By Acuity

51 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat